Background: The tradeoff in safety versus efficacy in substituting a non-vitamin K antagonist oral anticoagulant for a vitamin K antagonist (VKA) in the stented atrial fibrillation patient has not been quantitatively evaluated. Methods: Based on summary data from the PIONEER AF-PCI and RE-DUAL PCI trials, 4 antithrombotic regimens were compared with VKA-based triple therapy: (1) rivaroxaban (riva) 15 mg daily + P2Y 12 inhibitor, (2) riva 2.5 mg twice daily + P2Y 12 inhibitor + aspirin, (3) dabigatran (dabi) 110 mg twice daily + P2Y 12 inhibitor, and (4) dabi 150 mg twice daily + P2Y 12 inhibitor. A bivariate model with a noninferiority margin of 1.38 was used to simultaneously assess safety and efficacy. The safety end point was major or clinically relevant nonmajor bleeding by International Society on Thrombosis and Haemostasis definitions. The efficacy end point was a thromboembolic event (myocardial infarction, stroke, or systemic embolism), death, or urgent revascularization. The bivariate outcome, a measure of risk difference in the net clinical outcome, was compared between antithrombotic regimens. Results: All 4 non-vitamin K antagonist oral anticoagulant regimens were superior in bleeding and noninferior in efficacy compared with triple therapy with VKA. Riva 15 mg daily and 2.5 mg twice daily were associated with bivariate combined risk reductions of 5.6% (2.3%-8.8%) and 5.5% (2.1%-8.7%), respectively, and dabi 110 mg twice daily and 150 mg twice daily reduced the bivariate risk by 3.8% (0.5%-7.0%) and 6.3% (2.4%-9.8%), respectively. Conclusions: A bivariate analysis that simultaneously characterizes both risk and benefit demonstrates that riva-and dabi-based regimens were both favorable over VKA plus dual antiplatelet therapy among patients with atrial fibrillation undergoing PCI.
therapy has been associated with a greater risk of major hemorrhage, 8, 9 and this risk of bleeding has prompted efforts to develop new antithrombotic strategies. Until recently, 2 randomized controlled trials (PIONEER AF-PCI 10 and RE-DUAL PCI 11 ) compared the safety and efficacy of nonvitamin K antagonist oral anticoagulant (NOAC) to triple therapy and demonstrated significant bleeding reduction with comparable ischemic outcomes. However, the simultaneous tradeoff between bleeding and ischemic outcomes has not been quantitatively evaluated.
The present study aims to compare the risk-benefit profile of NOACbased antithrombotic regimens versus VKA-based triple therapy based on the results of PIONEER AF-PCI trial and RE-DUAL PCI trial. We applied a previously developed bivariate analysis approach 12 to assess the net clinical benefit (NCB) of therapy that simultaneously weighs thromboembolism, death, and urgent revascularization against bleeding risks.
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Methods
Data extraction and study end points
Two randomized controlled trials that compared NOAC-based anticoagulation with VKA in AF patients undergoing coronary stenting were included: PIONEER AF-PCI (ClinicalTrials.gov: NCT01830543) and RE-DUAL PCI (ClinicalTrials.gov: NCT02164864). 10, 11 In the PIONEER AF-PCI trial, the primary safety end point was the occurrence of clinically significant bleeding (a composite of major bleeding, minor bleeding, or bleeding requiring medical attention according to the Thrombolysis in Myocardial Infarction criteria) and the secondary efficacy end point was the occurrence of a major adverse cardiovascular event (a composite of death from cardiovascular causes, myocardial infarction, or stroke). In the RE-DUAL PCI trial, the primary safety end point was major or clinically relevant nonmajor bleeding event as defined by International Society on Thrombosis and Haemostasis (ISTH) and the secondary efficacy end point was a composite of thromboembolic events (myocardial infarction, stroke, or systemic embolism), death, or unplanned revascularization. For the purpose of homogeneity in study end points, the present study selected ISTH major or clinically relevant nonmajor bleeding as the safety end point as used in the RE-DUAL PCI trial, and the composite of thromboembolic event, death, or urgent revascularization as the efficacy end point, again as used in the RE-DUAL PCI trial. The frequencies of safety and efficacy events were extracted from secondary analysis of the PIONEER AF-PCI trial and published results of the RE-DUAL trial.
10,11
Study interventions
In the PIONEER AF-PCI trial, 2,124 patients were randomly assigned to (1) rivaroxaban 15 mg once daily + P2Y 12 inhibitor (clopidogrel, ticagrelor, or prasugrel for 12 months), (2) rivaroxaban 2.5 mg twice daily + P2Y 12 inhibitor (clopidogrel, ticagrelor, or prasugrel for 1, 6, or 12 months) + aspirin, and (3) dose-adjusted VKA + P2Y 12 inhibitor (clopidogrel, ticagrelor, or prasugrel for 1, 6, or 12 months) + aspirin. In the RE-DUAL PCI trial, 2,725 patients were randomized to (1) dabigatran 110 mg twice daily + P2Y 12 inhibitor (clopidogrel or ticagrelor for 12 months), (2) dabigatran 150 mg twice daily + P2Y 12 inhibitor ⁎ All 95% CIs of the risk differences exclude the noninferiority margin of +5.7%.
(clopidogrel or ticagrelor for 12 months), and (3) dose-adjusted VKA + P2Y 12 inhibitor (clopidogrel or ticagrelor for 12 months) + aspirin (for 1-3 months). To compare the safety and efficacy of NOAC-based regimens across the studies, VKA-based triple therapy (VKA plus background dual antiplatelet therapy) was selected as the control group. Similarly, the treatment effect of rivaroxaban-based regimen and dabigatran-based regimen was compared with that of VKA-based triple therapy. An additional comparison was made between reduced-dose NOAC-based regimen (combination of rivaroxaban 15 mg once daily regimen and dabigatran 110 mg twice daily regimen) and VKA-based triple therapy.
Statistical analysis
The noninferiority hypothesis for the efficacy was tested in the PIONEER AF-PCI trial to compare the effect of rivaroxaban dosing strategies with VKA on the composite of thromboembolic events, death, or urgent revascularization (Table I ). The upper boundaries of 95% CI of relative risk for rivaroxaban dosing strategies were less than 1.38 (the noninferiority margin used in the RE-DUAL PCI trial). Again, to maintain consistency in the bleeding end point, the same bleeding definition used in RE-DUAL PCI trial (ISTH major or clinically relevant non-major bleeding) was applied to both studies.
Detailed methodology of the bivariate analysis has been described previously by Kittelson et al. 12, 14 In brief, risk differences in safety (RD S ) and efficacy (RD E ) were calculated by subtracting the event rate of the control group from the event rate of the treatment groups. A structured 2-dimensional plane was thus defined by RD S and RD E , with the lower left quadrant representing reduction in both safety end point (major or clinically relevant nonmajor bleeding) and efficacy end point (thromboembolic event, death, or urgent revascularization). The 95% Wald CIs of RD S and RD E were reported in Table II and summarized as a rectangle on the plane in Figure 1 .
Clinically important risk difference was set at 15% to approximate the maximum effect size among the 4 NOAC-based regimens (Table II) . The noninferiority margin was set at 1.38 in accordance with the methods recommended by the Food and Drug Administration for the evaluation of NOAC in stroke prevention. 15 Consequently, in the present analysis, the acceptable threshold for excessive risk difference (NI S and NI E ) was set at 5.7% (ie, the rate of safety or efficacy outcome in the treatment group cannot exceed that in the control group by more than 5.7% when the maximum effect size is reached). Derivation of the NCB curve is provided in the Supplementary Material.
12,14
The NCB curve divided the risk-benefit plane into 2 regions: lack-ofbenefit region versus benefit region ( Figure 1) . The lack-of-benefit region was defined as the partition above the curve. The risk-benefit profile was deemed favorable against the control group if the 95% CI rectangle did not contain the lack-of-benefit region. Furthermore, bivariate outcomes were quantitatively assessed by the minimum distance from the NCB curve to 3 reference points: (1) center of the rectangle, representing the point estimate of the bivariate outcome; (2) southwest corner of the rectangle, representing the lower boundary of the bivariate outcome; and (3) northeast corner of the rectangle, representing the upper boundary of the bivariate outcome. Accordingly, the collective treatment effect on safety and efficacy was presented as a point estimate along with a range of bivariate risk difference. Although their technical statistical properties are different, these metrics are analogous to reporting the point estimate with 95% CI; that is, positive values indicate increased risk, and negative values indicate decreased risk. Finally, a sensitivity analysis was performed to test a spectrum of noninferiority margins, ranging from a more stringent margin of 1.14 (used in the ENCHANTED trial for evaluating the impact of thrombolysis on death or disability 16 ) to a less stringent margin of 1.35. The work was supported by research grants from Janssen Scientific Affairs and Bayer, the sponsors of the study. The authors are solely Figure 1 . Interpretation of the bivariate analysis. Qualitatively, a favorable NCB is established if the rectangle defined by 95% CI of risk difference does not include the lack-of-benefit region. Quantitatively, the bivariate outcome is measured by the minimum distance from the curve to the center (point estimate), southwest corner (lower bound), and northeast corner (upper bound) of the rectangle. responsible for the design and conduct of this study, all study analyses, the drafting and editing of the manuscript, and its final contents.
Results
Summary of trial results
Noninferiority in efficacy and superiority in bleeding was first assessed separately (Tables I and II ). The rivaroxaban-based regimens and the dabigatran 150 mg twice daily regimen were noninferior to VKA triple therapy with respect to the RE-DUAL efficacy end point (Table I ). The superiority of rivaroxaban-based or dabigatran-based therapy over VKA with respect to bleeding has been demonstrated previously (Table II) . 10, 11 Qualitative assessment of the bivariate outcome Although the above analyses evaluate safety and efficacy separately, a bivariate analysis was performed to assess safety and efficacy simultaneously. Results of 4 antithrombotic regimens were expressed as a rectangle defined by the 95% CI of risk difference in safety and efficacy on the risk-benefit plane (Figure 2 ). The 0.00% vertical line and 0.00% horizontal line represented the superiority boundary for safety and efficacy, respectively. The rectangles for all 4 NOAC-based regimens were on the left to the vertical line, indicating that these regimens achieved superiority in bleeding compared with VKA. The 4 rectangles crossed the horizontal line, indicating that superiority in efficacy was not achieved. Similarly, rivaroxaban-based regimen, dabigatran-based regimen, and reduced dosing strategy were superior in safety when compared with VKA-based triple therapy (Figures 3 and 4) .
The NCB curve was derived using a noninferiority margin of 1.38 (corresponding to an acceptable threshold for an excessive risk difference of 5.7%) and divided the plane into 2 regions. The rectangles of the 4 NOAC-based regimens did not contain the partition above the curve (lack-of-benefit region), indicating that these regimens were favorable over VKA (Figure 2 ). Similar risk-benefit profiles were observed in rivaroxaban-or dabigatran-based regimen as well as reduced-dose regimen (Figures 3 and 4) . Analysis of the pooled data suggested that NOAC-based regimen was superior in safety and noninferior in efficacy ( Figure 5 ).
Quantitative assessment of the bivariate outcome
Quantitatively, bivariate outcomes were assessed by the minimum distance from the NCB curve to the center (point estimate) and opposing corners of the rectangle (upper and lower boundaries). The effect size in terms of bivariate outcome was then summarized in the forest plot ( Figure 6 ). Rivaroxaban 15 mg once daily and 2.5 mg twice daily were associated with a bivariate risk reduction of 5.6% (2.3%-8.8%) and 5.5% (2.1%-8.8%), respectively, and dabigatran 110 mg twice daily and 150 mg twice daily reduced the risk by 3.8% (0.5%-7.0%) and 6.3% (2.4%-9.8%), respectively. Both the combined 2.5 mg and 15 mg rivaroxabanbased and the combined 110-and 150-mg dabigatran-based regimens were favorable over VKA, with a bivariate risk reduction of 5.6% (3.2%-7.8%) and 4.9% (2.5%-7.3%), respectively. The reduced-dose regimens of 15 mg rivaroxaban and 110 mg dabigatran and all 4 NOAC-based regimens combined demonstrated comparable bivariate risk reductions over VKA of 4.5% (2.2%-6.8%) and 5.5% (3.4%-7.5%), respectively ( Figure 6 ).
Sensitivity analysis of the noninferiority margin
In the sensitivity analysis, a spectrum of noninferiority margin (ie, 1.14, 1.20, 1.25, 1.30, and 1.35) was used to test the robustness of treatment effects of NOAC-based regimens (Figures S1-S5 ). Rivaroxaban 15 mg daily and rivaroxaban 2.5 mg twice daily maintain an advantage over VKA when the noninferiority margin is set at 1.25. Dabigatran 110 mg twice daily and dabigatran 150 mg twice daily maintained an advantage over VKA when the margin was set at 1.35 and 1.20, respectively. When all 4 regimens were taken together, the NOAC-based regimens showed a favorable profile at the noninferiority bound of 1.14. In other words, if a 2.1% threshold of risk difference is clinically acceptable, NOAC would be preferred over VKA in the bivariate model that weighs thromboembolism, death, and urgent revascularization against bleeding risks.
Discussion
Clinicians must consider bleeding and ischemic outcomes simultaneously when making a decision regarding antithrombotic management in AF patients undergoing stent placement. The superiority of rivaroxaban-based or dabigatran-based therapy over VKA-based strategies with respect to bleeding has been demonstrated previously. 10, 11 If a regimen is safer, then with respect to efficacy, noninferiority instead of superiority is a reasonable goal. The advantage of a bivariate analysis is that it potentially allows one to evaluate if whether a regimen is superior in safety and simultaneously noninferior in efficacy yielding an overall NCB. 13, 14 The efficacy end point in RE-DUAL was used for the noninferiority analysis because it was broader and yielded more events than the narrower end point used in the PIONEER study (ie, myocardial infarction, stroke, and cardiovascular death). When weighed against the same scale of bleeding risk, both rivaroxaban-based and dabigatranbased regimens were favorable over a VKA-based regimen. Using the efficacy end point from the RE-DUAL trial, the rivaroxaban regimens also achieve noninferiority when analyzed as the sole end point independent of safety using traditional statistical methods. Results from the PIONEER AF-PCI trial and RE-DUAL PCI trial both demonstrate that NOAC-based anticoagulation plus background antiplatelet therapy can be a desirable alternative to VKA-based triple therapy. One simple approach to assess NCB is to subtract the event rate of safety outcome from the rate of efficacy outcome. The linear function of these conventional approaches treats the tradeoff as symmetrical and unlimited. Thus, a substantial increase in bleeding would be inappropriately deemed acceptable given a corresponding reduction in thromboembolism. A more sophisticated approach, however, is to calculate NCB in a bivariate model, which is a novel statistical method devised to characterize the nonlinear nature of tradeoffs in a 2-dimensional outcome. 13, 14 The bivariate model is a weighted aggregate of risk difference determined by the relative impact of treatment on safety versus efficacy. 17 The output includes a qualitative display on the safetyefficacy plane and a quantitative comparison of the risk difference as the bivariate outcome. The bivariate approach has been used to compare the risk-benefit profile of anticoagulation and antihypertensive strategies and to devise the stopping criteria for the interim analysis. 14, [18] [19] [20] Furthermore, in the Kids-DOTT trial (ClinicalTrials.gov Identifier: NCT00687882), the bivariate end point was used as the primary outcome measure to gauge the tradeoff between the risks of recurrent venous thromboembolism and bleeding associated with shortened-duration versus conventionalduration anticoagulation. This approach could be a valuable addition to the conventional tools to evaluate the risk-benefit balance of treatment.
As in the interpretation of unidimensional outcome, inference derived from the bivariate model may be affected by the choice of noninferiority margin. There are no historical data to guide the determination of noninferiority margin for the end point of bleeding and thromboembolic events in the population of AF with stent placement. This study adopts the noninferiority margin of 1.38, as recommended by the regulatory agency for NOAC trials in the assessment of stroke prevention, 15 which has been considered as the most clinically relevant available reference. 21 Thus far, there is no consensus on the best practice for simultaneously analyzing multiple disparate end points to appraise the NCB of antithrombotic regimens. 22, 23 Nevertheless, results from the present analysis inform future trials regarding the extent of excessive thromboembolic risks that may be considered acceptable provided the substantial benefits in bleeding reduction with NOAC-based regimens.
Limitations
The present analysis evaluates the tradeoff between the primary safety end point (clinical significant bleeding) and the primary efficacy end point (thromboembolism, death, and urgent revascularization), which presumably have comparable clinical impact. Patient values and preferences were not considered when assessing the risk-benefit of antithrombotic regimens. The tradeoff between the components of the safety and efficacy composite end points (for instance, Thrombolysis in Myocardial Infarction major bleeding vs myocardial infarction) was not assessed, although it may also be of clinical interest. It is also noteworthy that the present analysis did not account for multiple or recurrent events. In addition, study-level data instead of individual-level data were analyzed in the bivariate model without accounting for potential between-study variance in treatment effects. Furthermore, both included trials were powered for the bleeding end point rather than the quantified bivariate outcome in this analysis. Finally, only 12% and 9% of the PIONEER and RE-DUAL study participants presented with STEMI and had primary PCI as the index event. More data are required to confirm the NCB of NOAC-based regimen in this subset.
Conclusions
In the management of AF patients who received coronary stenting, both rivaroxaban-based and dabigatran-based regimens were favorable over VKA plus dual antiplatelet therapy in a bivariate analysis that weighs thromboembolism, death, and urgent revascularization against bleeding risks.
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